Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW)

NCT01202591 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01202591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01202591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2010
Completion date
October 31, 2014
Enrollment
127 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

er+ breast cancer, fgfr inhibition, pharmacokinetics, biomarkers